2026 BLOOM BURTON AWARD GALA

PROGRAM

September 24, 2026

The Ritz-Carlton, Toronto

181 Wellington Street West, Toronto, Ontario



Table of Contents

Welcome from Bloom Burton & Co.	5
Agenda	7
Message from Oliver Technow	8
Message from the Prime Minister of Canada	10
Message from the Premier of Ontario	12
Message from the Mayor of Toronto	14
Finalists	17
Musical Performances	26
Judges	28
Table Sponsors	36



Welcome from Bloom Burton & Co.

Welcome to the 10th Bloom Burton Award Gala!

We are delighted to welcome you to the elegant Ritz-Carlton, Toronto, as we celebrate those who have made exceptional contributions to Canada's innovative healthcare industry over the past year.

For ten years, this gala has recognized the innovators, entrepreneurs, researchers, and leaders driving progress across the healthcare sector. Tonight we are proud to mark a decade of honouring those whose vision and achievements continue to advance the industry and improve the lives of patients.

The Bloom Burton Award recognizes outstanding contributions to healthcare from any role, field or stage of development. The award celebrates those who advance medical science, attract or provide risk capital, launch transformative products or companies, or influence policy in ways that create meaningful impact on the global stage.

For 2026, the nominations submitted by the public at large were reviewed by our distinguished international judging panel. The following individuals, in alphabetical order, were selected as finalists:

- Ian Mortimer, President & Chief Executive Officer, Xenon Pharmaceuticals
- Graham Rosenberg, Chairman & CEO, and Nate Tchaplia, President & CFO, Dentalcorp
- Ilia Tikhomirov, Former Chief Executive Officer, 35Pharma

This year's finalists represent exceptional leadership and achievement across the healthcare industry. Their contributions span innovative drug development, the creation of a national dental network, and the advancement of Canadian biotech entrepreneurship. Please join us in honouring their accomplishments and toasting their lasting impact on Canadian healthcare.

Sincerely,



Brian Bloom



Jolyon Burton



Agenda

6:00 PM Cocktail Reception

7:00 PM Bloom Burton Award Program & Dinner

Welcome Remarks
Brian Bloom & Jolyon Burton

Musical Performance
Gabi Epstein

Celebrating Ian Mortimer
2026 Bloom Burton Award Finalist

Celebrating Graham Rosenberg & Nate Tchaplia
2026 Bloom Burton Award Finalists

Celebrating Ilia Tikhomirov
2026 Bloom Burton Award Finalist

Musical Performance
Adrian Marchuk

2026 Bloom Burton Award Winner Announcement
Oliver Technow, 2025 Bloom Burton Award Winner

10:00 PM Networking

Oliver Technow

2025 Bloom Burton Award Winner



Celebrating Ambition, Innovation, and Outstanding Leadership

Standing on stage last year as the recipient of the 2025 Bloom Burton Award was one of the most humbling and proudest moments of my career. It was a moment that reflected not just a personal or organizational milestone, but the collective strength, resilience, and world-class potential of Canada's life sciences ecosystem.

Receiving this award last year also reminded me that none of us builds in isolation. The people, partners, scientists, investors, clinicians and patients who surround us and our companies are what turn ambition into true impact.

Today, we live in a world where every morning seems to bring a new, unprecedented, and highly unwelcome challenge. We must adapt to the impacts of escalating geopolitical tensions, dramatic economic shifts and an era of global uncertainty. Yet, amidst this turbulence, our sector stands tall as a vital beacon of steadiness. While the news cycles remind us of the world's fragilities, life sciences consistently deliver progress, transforming uncertainty into hope and providing tangible, life-saving advancements for humanity.

Looking back over the past twelve months, that momentum has not simply sustained - it has accelerated. We are witnessing a fundamental shift in Canadian pharma and biotech. We have moved beyond proving that world-class science happens here; we are now demonstrating that world-class execution, commercialization, and scale happen here.

Three defining forces over the last year illustrate just how far our sector has come and will continue to evolve and lead:

1. **Policy Aligning with Purpose:** The rollout of regulatory and access modernization signals a crucial shift toward delivering innovation to patients faster and more efficiently.
2. **Global Scale on Canadian Soil:** From major infrastructure expansions in biomanufacturing to world-leading biopharma partnerships, Canada is solidifying its position as a global anchor for advanced manufacturing and complex biological supply chains.
3. **M&A and Global Validation:** The continued appetite from international healthcare leaders to deploy capital into Canadian platforms - evidenced by multi-billion-dollar acquisitions and cross-border strategic roll-ups - proves that Canadian discovery commands top-tier global valuation.

None of this progress happens by chance. It is driven by inspirational and relentless leaders who dare to build, scale, and transform possibilities into clinical and commercial reality. This brings us to the heart of this evening's celebration: our three exceptional 2026 Bloom Burton Award finalists! Once again, we are coming together – now for the 10th time! - under the gracious hospitality of Brian Bloom and Jolyon Burton to celebrate outstanding individuals that make us proud to be part of our sector.

To Ian, Graham and Nate, and Ilia: congratulations! You embody what makes our sector so strong and successful. We are so proud of you and all you have already accomplished. Your achievements inspire our entire community and set the benchmark for what is possible. I can't wait to celebrate all of you.

To Brian, Jolyon and the entire team at Bloom Burton & Co.: thank you for your unwavering stewardship and for continuing to elevate Canadian innovation.

I can't help but be optimistic and excited. Our sector's best days are not behind us - they are unfolding right now. We are only getting started!

Let us celebrate the 2026 Bloom Burton Award finalists, toast to our collective progress, and keep relentlessly building and innovating for the patients who rely on us.


Warmest regards,

Oliver Technow

2025 Bloom Burton Award Winner

Mark Carney

Prime Minister of Canada



PRIME MINISTER · PREMIER MINISTRE

I would like to convey my warmest greetings to everyone attending the 2026 Bloom Burton Award Gala.

You have come together this evening to celebrate excellence and leadership in the healthcare field. I would like to offer my sincere congratulations to this year's award finalists. Your hard work has earned you the respect and admiration of your peers, and you can take pride in this very special recognition of your achievements.

I would also like to thank the organizers for ensuring the success of this event, as well as for promoting and supporting innovation in healthcare.

I wish you all a wonderful evening and continued success.



The Right Honourable Mark Carney, P.C., O.C., M.P.
Prime Minister of Canada

Ottawa
2026

Doug Ford

Premier of Ontario



Ontario

Premier of Ontario - Premier ministre de l'Ontario

September 24, 2026

A MESSAGE FROM PREMIER DOUG FORD

Tonight, you gather to recognize the outstanding innovators who, over the past year, have made remarkable contributions to the country's health-care sector. Welcome to the Bloom Burton Award Gala!

Congratulations to this year's finalists: Ian Mortimer of Xenon Pharmaceuticals, Graham Rosenberg and Nate Tchaplia of Dentalcorp, and Ilia Tikhomirov of 35Pharma. We have some of the best minds working in our health-care industry and your achievements are proof of that.

Many thanks to the amazing people behind Bloom Burton & Co. for hosting this event and for working tirelessly to create opportunities for both companies and investors.

As you know, our government is focused on strengthening the province's standing as a global hub for health research, technology and innovation. Organizations like yours are valued partners in helping bring made-in-Ontario solutions to the next level. Together, we can support the development of new technologies and medicines that will improve patient outcomes and transform our health-care system for generations to come.

Have a memorable evening!



Doug Ford
Premier

Olivia Chow

Mayor of Toronto



CITY OF TORONTO

WELCOME FROM THE MAYOR OF TORONTO

It is my pleasure to welcome everyone attending the 2026 Bloom Burton Award Gala, hosted by Bloom Burton & Co.

The Bloom Burton Award recognizes an individual scientist, inventor, executive, entrepreneur, industry leader or policymaker for contributions to health care and related industries over the previous year. The event provides an opportunity to acknowledge work in research, development and innovation across the sector.

Congratulations to this year's nominees and thank you for your contributions to Canada's health care industry.

The City of Toronto recognizes the role of research, development and investment in supporting the continued advancement of health care.

On behalf of Toronto City Council, best wishes for an enjoyable and memorable event.

Yours truly,



Olivia Chow
Mayor of Toronto

City Hall, 100 Queen Street West, 2nd Floor, Toronto, Ontario M5H 2N2
416-397-CITY (2489) mayor_chow@toronto.ca

2027 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE



MAY 11 & 12

Finalists

Our finalists are celebrated for their exceptional contributions to Canadian healthcare. Each finalist has received a $25,000 cash prize, and a single winner will have the honour of being the recipient of the 2026 Bloom Burton Award.



Ian Mortimer



Graham Rosenberg



Nate Tchaplia



Ilia Tikhomirov



Ian Mortimer

President and Chief Executive Officer, Xenon Pharmaceuticals

Ian Mortimer has served as Xenon's President and Chief Executive Officer since June 2021. He has held several roles of increasing responsibility since joining Xenon in 2013 as our Chief Financial Officer, including President, Chief Operating Officer, and Corporate Secretary.

Before Xenon, Mr. Mortimer was the Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma Corporation), where he managed the company's finances and capital markets activities, including leading their Nasdaq listing in 2010.

His earlier career included serving as Chief Financial Officer at Inex Pharmaceuticals, which he joined in 1997. Mr. Mortimer also lends his expertise to the board of directors for BIOTECanada. He earned his M.B.A. from Queen's University, his B.Sc. in microbiology from the University of British Columbia, and is a Chartered Professional Accountant.



Graham Rosenberg

Chief Executive Officer and Chairman, Dentalcorp

Graham Rosenberg is a Canadian entrepreneur, investor and company builder, best known as the founder, Chief Executive Officer and Chairman of Dentalcorp, one of North America's largest and fastest growing networks of dental practices.

Rosenberg founded Dentalcorp in 2011 around a partnership model designed to provide dentists with the benefits of scale, capital, technology and professional management while allowing them to retain clinical autonomy. Under his leadership, Dentalcorp expanded across Canada and into the US, to more than 650 locations, supported by more than 10,000 team members and serving approximately six million patient visits annually.

In May 2021, Rosenberg led Dentalcorp through its initial public offering on the Toronto Stock Exchange. The offering raised more than $950 million and was, at the time, the largest healthcare IPO in Canadian history. In January 2026, Rosenberg subsequently led Dentalcorp through its $3.3 billion take-private transaction alongside GTCR LLC.

Through Dentalcorp, Rosenberg has also supported initiatives aimed at expanding access to oral healthcare, including the Give Back, Smile Back program and philanthropic commitments supporting pediatric dentistry and dental education across Canada.

Before founding Dentalcorp, Rosenberg built a career in private equity, principal investing and corporate development. His career has focused particularly on consolidation strategies, partnership-based business models and building companies at scale.

Rosenberg's entrepreneurial achievements have been well recognized, most recently winning the 2023 EY Entrepreneur Of The Year Award for Ontario.

Rosenberg is a Chartered Professional Accountant and holds both a Bachelor of Business Administration and a Master of Business Administration from the Schulich School of Business at York University.



Nate Tchaplia

President and Chief Financial Officer, Dentalcorp

As President and CFO of Dentalcorp, Nate Tchaplia is responsible for the company's long-term strategy and day-to-day operations. With over a decade of experience at Dentalcorp, Nate has held several key positions, including Head of Operations, where he drove efficiency and innovation across multiple departments.

During his tenure with Dentalcorp, Nate has led several teams, including Business and Corporate Development, Operations, Procurement, Real Estate, and Technology. His expertise in valuations, mergers and acquisitions, and capital advisory has been instrumental in steering Dentalcorp's financial and operational strategy.

Before joining Dentalcorp, Nate honed his skills at an international advisory and consulting firm, where he gained a deep understanding of financial markets and strategic financial planning. This experience, combined with his background as a Chartered Professional Accountant and his Bachelor of Commerce degree from McGill University, provides him with a solid foundation to lead Dentalcorp into its next phase of growth.



Ilia Tikhomirov

Former Chief Executive Officer, 35Pharma

Ilia is a serial biotech entrepreneur and executive who has helped build multiple companies that achieved successful M&A exits. Most recently, Ilia helped found 35Pharma, a clinical stage pulmonary hypertension company that was acquired by GSK.

Prior to 35Pharma, he helped found Forbius, a clinical stage fibrosis and immunooncology company which was acquired by Bristol Myers Squibb. Prior to that, Ilia held various roles at YM Biosciences until its acquisition by Gilead.

Ilia holds an MBA and a Master of Biotechnology from the University of Toronto.

Musical Performances


Gabi Epstein



Performing at the Bloom Burton Award Gala for the third year in a row is multi-award winning singer, actor, and recording artist Gabi Epstein - one of the country's most sought after performers best known for playing Fanny Brice in the Segal Centre's production of Funny Girl and Audrey in the Stratford Festival's production of Little Shop of Horrors.

With a professional career of over 20 years, some highlights include starring in the Tony Award winning musical Once at the Ed Mirvish Theatre, performing in Billy Elliot on the Stratford Festival Theatre stage with a 45 piece orchestra and 30 other cast members, singing the role of Eponine in Les Miserables: In Concert with orchestra, starring in the Canadian Premiere of Andrew Lloyd Webber's award-winning one-woman show Tell me on a Sunday, and performing for musical legends Alan Menken, Steven Schwartz and Marc Shaiman on various occasions.

"Hailed as Canada's Queen of Cabaret" by CTV, Gabi has two studio albums - Show Off (released in 2010) and Gabs Sings Babs - a love letter to Barbra Streisand (released in 2022). The latter was turned into a solo-show (also called Gabs Sings Babs) where Gabi, often called "Canada's Barbra Streisand" questions why she can't simply be known as "Canada's Gabi Epstein". Using reimagined new arrangements of Streisand's most iconic hits, Gabi goes on a journey to rediscover the "Gabs" in all of the "Babs". Her show has been performed to sold-out audiences all over Canada.



Adrian Marchuk

Adrian is the creator and co-producer of four hit concert musicals - Any Dream Will Do, The Sweetest Sounds, Over The Rainbow, and A Whole New World. By taking us behind-the-scenes and inside the lives of the greatest composers of Broadway and Hollywood, Adrian and his co-producer Brian Goldenberg are bringing audiences to their feet across Canada.

Adrian spent three years playing Frankie Valli in the Toronto and Las Vegas companies of Jersey Boys. Other recent credits include starring in Marry Me A Little (Tarragon Theatre), Dr. Fine in the hit rock musical Next To Normal (Tarragon Theatre), Fabrizio in The Light in the Piazza (Patrick Street Productions, Persephone Theatre), Gilbert Blythe in Anne & Gilbert (Ontario Tour), Musical Of Musicals (Mirvish), and the Canadian premiere of The Apprenticeship of Duddy Kravitz.

Adrian's newest show is co-created with fellow Jersey Boys star Jeff Madden - How We Got To Jersey: A Tale Of Two Frankies takes you behind the scenes of the smash hit world phenomenon Jersey Boys by delivering not one, but TWO Frankie Vallis in one show!

Adrian also teaches voice privately from his home in Toronto, where he lives with his wife and his 5 kids.

Judges

Our esteemed panel of judges are respected international leaders in healthcare investment, entrepreneurship and journalism.





Michael Altman

Head of Strategy, Perceptive Advisors

Michael Altman serves as the Head of Strategy for Perceptive's investment team and is a member of the investment committees for Perceptive's Credit Opportunities and Capital Solutions Funds. He is responsible for managing the firm's investments in medical devices, diagnostics and health technology.

Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration.

Michael serves on the board of directors for Perceptive Capital Solutions Corp. and Talkiatry.

Christopher Arendt

Chief Scientific Officer, Head of Research, Takeda



Based at Takeda's Cambridge, Massachusetts, R&D campus, Christopher Arendt is responsible for oversight of Takeda's Research and Early Development portfolio across Takeda's core therapeutic areas of Gastroenterology and Inflammation, Oncology, and Neuroscience. Since joining Takeda in 2015, Christopher has helped reshape Takeda's pipeline with a strong network of top-tier global collaborators, emphasizing emerging science leveraging a breadth of mechanisms and modalities, including allogenic innate immune cell therapies, antibody-targeted small molecules and oligonucleotides, and cutting-edge biologics.

Christopher is a Ph.D. Immunologist who carried out postdoctoral training with Dan Littman at New York University Medical Center.

Prior to joining Takeda, Christopher spent more than 13 years at Sanofi, where he led global teams advancing novel immunotherapies for cancers and inflammatory diseases.



Karen Bernstein

Co-Founder and Chairman, BioCentury Inc.

Karen is Co-Founder and Chairman of BioCentury Inc. and was Editor in Chief from October 1992 to August 2015.

She is also chairman of The Critical Path Institute, a non-profit that leads collaborations to accelerate drug development, and is a director at Mind What Matters, a non-profit serving caregivers for Alzheimer's patients. She has served on multiple boards, including most recently at Ovid Therapeutics Inc., which is developing drugs for neurological diseases, and on the Board of Trustees of the Keck Graduate Institute.

Karen holds a Ph.D. in Political Science from Stanford University and a B.A. in Politics and History from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council.

Joan Eliasek

President, North-American Pharmaceutical Distribution, McKesson



Joan Eliasek serves as President, North American Pharmaceutical Distribution. In her role, Joan leads the North American Pharmaceutical segment, which ensures the safe and reliable delivery of medicines and therapies across the U.S. and Canada, and partners with stakeholders across the healthcare ecosystem to deliver insights, products, technology and services that help make quality care more accessible and affordable.

Joan joined McKesson in 1995 and has held a variety of leadership roles across the company, including operations, sales, marketing and supplier management. Most recently, Joan served as President, McKesson Canada, leading McKesson's portfolio of businesses in Canada, including pharmaceutical distribution operations, Specialty Health and McKesson's network of independent pharmacies comprised of I.D.A., Guardian, Remedy'sRx, The Medicine Shoppe, Uniprix and Proxim.

Prior to that, Joan served as Senior Vice President, Customer Experience, for McKesson's Medical-Surgical business unit, leading operations, customer service, materials management, sales administration and data management. Earlier in her career, Joan held multiple management positions in field operations at Baxter Healthcare Corporation.

Joan has served on several boards in the healthcare industry, including Healthcare Industry Distributors Association (HIDA), HIDA Educational Foundation and Global Healthcare Exchange. She is also a long-time advisor to the Professional Women in Healthcare (PWH) board. In 2018, Joan was the first recipient of the Anne Eiting Klamar Leadership Award of Distinction by PWH. Joan was also inducted into the Repertoire Medical Distribution Hall of Fame in 2023.

Joan received her Bachelor of Arts in Political Science and Business Administration from the University of Iowa.



Carl Gordon

Managing Partner, OrbiMed


Carl is a Managing Partner and leads OrbiMed's private equity team. Carl joined OrbiMed's predecessor firm in 1995 and was a founding General Partner of OrbiMed in 1998. He did his undergraduate work at Harvard (A.B., Chemistry & Physics, 1987), worked at the biotechnology company Imclone Systems (1987-1988), then attained a Ph.D. in Biology from MIT (1993), and was a Postdoctoral Fellow at the Rockefeller University (1993-1995).

Carl has been fortunate to have been on the Forbes Midas list of top venture capital investors multiple times. He has founded and invested in numerous biotechnology companies and served on many public and private company boards.

When considering investments, Carl looks for innovative technology and creative management teams and believes the key to success is a combination of integrity, hard work, and passion.

Dennis Purcell

Founder and Senior Advisor, Aisling Capital



Dennis is the original Founder of Aisling Capital LLC. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q") for over five years. Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Dennis is a frequent commentator on the industry and has been honored in the "Biotech Hall of Fame" by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Dennis received his M.B.A from Harvard Business School and his B.S in Accounting from the University of Delaware.



Camille Samuels

Director, Venrock Boards

Camille (Cami) focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. Temperamentally an early-stage investor and company helper, Cami currently serves on the board of Cavalry, Iris, and Mahzi. She previously served on the board of several exited Venrock portfolio companies, including Corvidia (sold to Novo), RegenXBio (RGNX), and Spirox (owned by Stryker).

Prior to Venrock, Cami was a Managing Director at Versant Ventures where she served on the board (or as a board observer) at many companies including Genomic Health (GHDX/ sold to Exact), Jazz (JAZZ), Kythera (KYTH/ sold to Allergan), and Novacardia (sold to Merck). During her early career, Cami worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and she was a management consultant at LEK.

Cami earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar. She is a Henry Crown Fellow, serves on the board of the EDS Society, as well as the Duke University RTC Council (research translation and commercialization), on the Investment Advisory Committee of Mission BioCapital (MBC), and on the HBS Global Advisory Board.

Table Sponsors

























































Thank you

for supporting our annual celebration of Canadian healthcare!

J.P.Morgan

juno

KYE Pharmaceuticals | Founded in Canada Focused on Canadians

LUMIRA VENTURES

mccarthy tetrault

McKESSON Canada

MEDEXUS PHARMA

MICROBIX

MINTZ

NATIONAL BANK

NeuPath Health Inc.

NRF

RBCX

ROSALIND

satellos

SEIDO CAPITAL

Stikeman Elliott

TIAP TORONTO INNOVATION ACCELERATION PARTNERS

TMX

TORYS LLP

troutman pepper locke

VERSANT ventures

Xenon

Zeifmans Ideas with impact Member of Nexia

Save the Date




Bloom Burton & Co. **Holiday Party**

November 26, 2026



2024 Bloom Burton Award winner Roberto Bellini congratulates
2025 Bloom Burton Award winner Oliver Technow



September 24, 2026

The Ritz-Carlton, Toronto

181 Wellington Street West, Toronto, Ontario